SKSabahattin Kaymakoglu

Sabahattin Kaymakoglu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sabahattin Kaymakoglu has a total of 349 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Seroepidemiological Prevalence of Hepatitis B and C Virus Coinfection: A Large-Scale Retrospective Cohort Study in Istanbul

    by Arat Hulikyan, Hayriye Kirkoyun Uysal, Gizem Dagci, Bilger Cavus, Sebahattin Kaymakoglu, Murat Hakan Kir, Arif Atahan Cagatay, Derya Sevimli Saydan, Mehmet Demirci, Ali Agacfidan, et al.

    Background/Objectives: Hepatitis B (HBV) and hepatitis C (HCV) coinfection leads to the progression of liver disease and results in clinically serious outcomes. Continuous monitoring of epidemiological data is crucial for managing the regional disease burden. This study investigates the current seroprevalence of HBV and HCV, the prevalence of coinfection, and the rates of active replication in Istanbul. Methods: This retrospective analysis included 7131 patients evaluated at the Infectious Diseases and Gastroenterohepatology clinics between 2021 and 2025. Initial serological screening for viral markers was performed using routine chemiluminescent immunoassays. Active viral replication was subsequently confirmed and quantified via real-time polymerase chain reaction (PCR). Results: Active HBV replication was significantly more frequent among patients in the Gastroenterohepatology clinic (20.47%) compared to those in Infectious Diseases (5.36%). Active HCV infections were rare in both departments (0.25% and 0.04%, respectively). Simultaneous HBV and HCV coinfection was detected in only 17 patients (0.24%). Demographic evaluation demonstrated that HBV marker positivity was more prevalent in male patients and individuals over 40 years of age. Conclusions: HBV seroprevalence remains substantially higher than HCV in this cohort. The high rate of active HBV replication in gastroenterohepatology settings indicates a concentrated burden of active disease in these specialized clinics. These distribution patterns emphasize the necessity of routine, targeted HBV screening for older male demographics to facilitate early clinical intervention.

  • Open Access

    Exocrine Pancreatic Insufficiency in Diabetes: Association with Cardiovascular Disease and Insulin Therapy

    by Melek Balamir, Bartu Avcı, Elara Coşan, Sinan Tanyolaç, Bilger Çavuş, Aslı Çifcibaşı Örmeci, Filiz Akyüz, Selman Fatih Beşışık, Sabahattin Kaymakoğlu, Hulya Hacısahinogullari, et al.

    Background/Objectives: Exocrine pancreatic insufficiency (EPI) is increasingly recognized in patients with diabetes; however, its clinical correlates remain poorly defined. This study aimed to determine the prevalence and clinical characteristics of EPI in patients with type 1 (T1DM) and type 2 diabetes mellitus (T2DM) and to evaluate its associations with diabetes-related complications and insulin therapy. Methods: A total of 200 patients with diabetes were screened, and 182 who met the inclusion criteria were included in the final analysis. EPI was diagnosed using fecal elastase-1 (FE-1). Clinical, biochemical, and complication-related data were collected. Factors associated with EPI were evaluated using univariate and multivariate logistic regression analyses. Among patients with T2DM, an inverse probability of treatment weighting–average treatment effect on the treated (IPTW-ATT) model was constructed to evaluate the association between insulin therapy and EPI. Propensity scores were estimated using baseline demographic and clinical covariates, and covariate balance after weighting was assessed using standardized mean differences (SMDs). Results: Exocrine pancreatic insufficiency was detected in 18.1% of patients, with prevalences of 21.2% in T1DM and 17.4% in T2DM. Cardiovascular disease was the only variable independently associated with EPI in multivariate analysis (OR = 3.25; 95% CI: 1.12–6.75; p = 0.028. Among patients with T2DM, insulin therapy was significantly associated with EPI in both unadjusted and IPTW-ATT analyses (weighted OR = 10.76; 95% CI: 1.85–62.76; p = 0.008) with a wide confidence interval reflecting sparse data. Cardiovascular disease also remained significantly associated with EPI in the weighted model (OR = 3.52; 95% CI: 1.22–10.15; p = 0.020). Conclusions: Exocrine pancreatic insufficiency is a clinically relevant condition in diabetes and shows a significant cross-sectional association with cardiovascular disease. In T2DM, insulin therapy was associated with a higher prevalence of EPI, although confounding by indication cannot be excluded. These findings suggest that evaluation of exocrine pancreatic function may be considered in high-risk diabetic subgroups, pending confirmation in prospective longitudinal studies.

  • Time of first diagnosis in liver cirrhosis: what has changed over time from etiology to stage of disease?

    by Zülal İsTemihan, Ahmet Oğuz Çelik, Arzu Taş, Dilek Deniz, Çağrı Muratoğlu, Kanan Nuriyev, Sezen Genç Uluçeçen, Aynura Rustamzade, Gizem Dağcı, Mehmet Akif Yağlı, et al.

    It was aimed to investigate the characteristics of cirrhosis etiology, stage at diagnosis, diagnostic methods, and complications with a 1-decade interval. The clinical and demographic characteristics of patients with cirrhosis at the time of diagnosis at a tertiary university hospital between 2005-2009 (first period) and 2019-2023 (second period) were retrospectively investigated. In total, 1311 patients were diagnosed with cirrhosis, of which 857 (65.4%) were men. Seven hundred and ninety-eight (60.9%) were diagnosed in the first period. Six hundred and ninety (52.6%) patients were decompensated at diagnosis. Child Turcotte Pugh score was more common in the second period. MELD-Na score was higher in the first period (p = 0.026). The presentation rate with decompensation was higher in the first period (p = 0.009). In the first period, 211 (26.4%), and in the second period, 134 (26.1%) patients were diagnosed in the emergency department. The others were diagnosed in the outpatient clinic. There was no difference in the conditions for diagnosing between periods (p = 0.898). The causes of cirrhosis were, in order, 22.6% HBV, 19.7% MASLD, 18.9% cryptogenic, 13.1% ALD, 10.1% HCV, 7.7% autoimmune liver diseases, 4% HDV, 2.1% other causes, and 1.8% genetic diseases. In the second period, the frequency of cirrhosis caused by viral etiologies decreased (p < 0.05), and the frequency of MASLD and ALD increased (p < 0.05). Over the past decade, viral factors in the etiology of cirrhosis have gradually decreased, MASLD and ALD have progressively increased. While patients were detected more in compensated states, a significant portion of patients are still diagnosed in the decompensated stage and in emergency clinics.

  • Comparison of MELD, MELD-Na, and MELD 3.0 scoring systems for transplant prioritization in the Turkish population: A multicenter study

    by Kenan Moral, Murat Harputluoğlu, Gülşah Fidan Özkumur, Doğancan Gavcar, Efe Erbay, Fatih Eren, Mehmet Refik Göktuğ, Amir Nazari, Sencan Acar, Derya Ari, et al.

    The Model for End-stage Liver Disease Sodium (MELD-Na) score predicts mortality in liver transplant candidates. MELD 3.0 has been proposed as an improved model for estimating mortality risk. This study evaluated MELD 3.0’s predictive accuracy for short-term mortality among Turkish liver transplant candidates and compared its performance with MELD and MELD-Na scores. Patients listed both for deceased donor transplants and living donor transplants were analyzed in the study. The discriminative abilities of MELD, MELD-Na, and MELD 3.0 scores were assessed using the area under the receiver operating characteristic curve (AUROC). Comparisons between AUROC values used the DeLong test. The most predictive cutoff for MELD 3.0 was determined using the Youden index. Transplant-free survival was analyzed using the Kaplan–Meier method, with survival curves compared using the log-rank test. A total of 1689 patients were included in this nationwide, multicenter study. Hepatitis B was the leading cause of cirrhosis (29%, n=491), followed by metabolic dysfunction–associated steatohepatitis (20%, n=335). For 3-month mortality, MELD 3.0 had the highest AUROC (0.753), followed by MELD-Na (0.747) and MELD (0.725). The most predictive cutoff values were 18 for MELD and 21 for MELD-Na and MELD 3.0. Both MELD-Na and MELD 3.0 outperformed MELD ( p p =0.17). MELD 3.0 and MELD-Na demonstrated superior performance to MELD in predicting 3-month mortality among Turkish liver transplant candidates, though their predictive accuracy was comparable. Further refinements are needed to enhance MELD 3.0’s clinical utility.


  • Open Access

    De Novo Malignancies after Liver Transplantation: A Multicenter Cohort Study of Incidence, Timing, and Outcomes*

    by Nilay Danış, Hüseyin Döngelli, Tarkan Ünek, Aylin Bacakoğlu, İlKer Turan, Abdullah Zeki Karasu, Fulya Günşar, Elvan Işık, Muhsin Murat Harputluoglu, Kutay Sağlam, et al.

    Background/Aims: De novo malignancies are an important long-term complication following liver transplantation (LT), driven bychronic immunosuppression and extended post-transplant survival. Understanding patterns by tumor type, timing, and patient characteristics is essential for optimized surveillance. This study aimed to evaluate the clinical characteristics and temporal trends of de novoneoplasms in LT recipients.Materials and Methods: A total of 6943 adult LT recipients from 16 Turkish centers were evaluated between 1999 and 2023). Two hundred eight patients with 220 histologically confirmed de novo malignancies (excluding hepatocellular carcinoma) were included. Patientswho died within 30 days or developed cancer within 90 days post-LT were excluded. Incidence and mortality rates were assessed acrosspost-transplant intervals.Results: Non-skin solid (53.2%), dermatologic (28.6%), and hematologic (18.2%) cancers were predominant. Most malignancies (76.8%)occurred within 10 years post-LT. Early-onset (<10 years) malignancies were more common in living donor recipients (62.7%, P = .001)and associated with higher mortality (39.6% vs. 11.8%, P < .001). Recipients ≤60 years exhibited a higher incidence of hematologiccancers (23.9% vs. 12.6%, P = .03) and increased mortality (39.4% vs. 27.0%, P = .05). In subgroup analysis, tacrolimus use was stronglyassociated with cutaneous squamous cell carcinoma (P = .004). Peak incidence occurred 2-10 years post-LT (≈13-14 per 1000 recipients), with non-skin solid tumors being the most frequent.Conclusion: De novo malignancies remain a significant long-term risk after LT, with outcomes influenced by tumor type, age, immunosuppression, and timing of onset. Risk-adapted surveillance and tailored oncologic management, particularly dermatologic screeningin tacrolimus-treated patients and enhanced surveillance during the 2-10 year post-transplant period are recommended to improvelong-term survival.Cite this article as: Danış N, Döngelli H, Ünek T, et al. De novo malignancies after liver transplantation: A multicenter cohort studyof incidence, timing, and outcomes. Turk J Gastroenterol. Published online February 20, 2026. doi:10.5152/tjg.2026.25748.

  • PRIMARY GASTROINTESTINAL SYSTEM LYMPHOMA: ANALYSIS OF EIGHT PATIENTS IN A SINGLE-CENTER COHORT

    by Zülal İsTemihan, Mehmet Yağlı, Pelin Telli, Gizem Dağcı, Sezen Genç, Bilger Çavuş, Aslı Çifcibaşı Örmeci, Filiz Akyüz, Kadir Demir, Fatih Beşışık, et al.

    Objective: This study aimed to investigate the features of eight patients diagnosed with primary gastrointestinal system lymphoma.Materials and Methods: The features of patients diagnosed with primary gastrointestinal system lymphoma between 2021 and 2024 at the İstanbul Faculty of Medicine, Department of Internal Medicine, Division of Gastroenterohepatology, were retrospectively investigated.Results: Of the eight patients, 5 (62.5%) were male. The mean age was 55.1±18.8 (28–70) years. 4 (50%) patients had diabetes mellitus, one had Crohn's disease, one had decompensated cirrhosis, and one had compensated cirrhosis. The most common complaint of patients was stomachache. One of the patients who presented with stomachache had volvulus, one had ascites infection, and one had acute pancreatitis. Intestinal T-cell lymphoma was diagnosed in two, Burkitt lymphoma (BL) in two, Hodgkin lymphoma in one, mantle cell lymphoma (MCL) in one, follicular lymphoma in one and B-cell non-Hodgkin's lymphoma in one patients. The diagnosis of 4 (50%) patients was made by surgical resection, 3 (37.5%) patients were diagnosed by endoscopic biopsy and 1 (12.5%) patient was computerized by ascites fluid cytological examination and endoscopic biopsy. Four patients had lymphoma involvement in the small intestine, one patient had stomach, one patient had stomach and small intestine, one patient had spleen, and one patient had stomach, small intestine, and pancreas involvement.Conclusion: Primary gastrointestinal system lymphomas are rare diseases that can present in a wide age range and very different clinical presentations, and the small intestine was the most common involvement site in our cohort.

  • Risk Factors for Primary Sclerosing Cholangitis Recurrence Following Liver Transplantation: A Multicenter Retrospective Analysis

    by Gupse Adali, Sencan Acar, Murat Harputluoğlu, Tonguç Utku Yılmaz, Hamdi Karakayalı, Zülal Istemihan, Sabahattin Kaymakoğlu, Çiğdem Arıkan, Murat Akyıldız, Nilay Daniş, et al.

    Background and Aims: Primary sclerosing cholangitis recurrence (rPSC) after liver transplantation (LT) is common; however, the factors contributing to rPSC are poorly understood. This study aimed to identify the risk factors for rPSC after LT and determine whether donor type affects rPSC. Methods: A multicenter retrospective cohort analysis was conducted on 174 patients with PSC who underwent LT between January 2000 and January 2024. Multivariable Cox models were used to evaluate risk factors for rPSC. The rPSC risk for living donor liver transplantation (LDLT) and deceased donor liver transplantation (DDLT) recipients was compared using Kaplan‐Meier survival curves and log‐rank tests. Results: Of the 174 recipients, 144 (83%) underwent LDLT and 30 (17%) underwent DDLT. Sixty‐four (37%) had inflammatory bowel disease (IBD) prior to LT. Thirty‐three patients (19%) had rPSC after LT. The median time to rPSC was 28 months (IQR 6‐252). Patients with rPSC were younger at the time of PSC diagnosis, and had a higher prevalence of biliary complications after LT and concomitant IBD than those without recurrence. Multivariable Cox regression identified LDLT (HR 3.92, 95% CI 1.06–14.51, p = 0.041), biliary complications (HR 2.18, 95% CI 1.05–4.54, p = 0.037), IBD (HR 2.42, 95% CI 1.20–4.89, p = 0.013), and acute cellular rejection (HR 2.43, 95% CI 1.08–5.48, p = 0.032) as independent risk factors for rPSC. Conclusions: This multicenter study identified LDLT, acute cellular rejection, IBD, and biliary complications as independent risk factors for rPSC. These findings underscore the need for individualized post‐transplant surveillance and provide important considerations for graft selection and perioperative management in patients with PSC, particularly in settings where LDLT is predominant.


  • Open Access

    Maternal and Fetal Outcomes of Pregnancies in Wilson’s Disease: A Single-Centre Real-Life Experience

    by Kadir Demir, Aslı Çifcibaşı Örmeci, Bilger Çavuş, Zülal İsTemihan, Sezen Genç, Alp Atasoy, Filiz Akyüz, Fatih Beşışık, Sabahattin Kaymakoğlu

    Background/Aims: This study aims to investigate the fetal outcomes and pregnancy course in patients with Wilson’s disease (WD). Materials and Methods: A total of 54 female patients with a diagnosis of WD and a history of pregnancy between 1985 and 2021 were retrospectively examined in a specifically WD outpatient clinic in the İstanbul Faculty of Medicine. Results: A total of 131 pregnancies in 54 patients were examined. The mean age at diagnosis of WD was 22.1 ± 10.8 years. The mean follow-up period of patients diagnosed with WD was 87 ± 80 months. Forty (74.1%) patients were diagnosed with hepatic, 5 (9.3%) neurological, and 9 (16.6%) with mixed involvement WD. The liver was cirrhotic in 68 (51.9%) pregnancies. Ninety-eight (74.8%) preg nancies resulted in live birth, 30 spontaneous abortions (22.9%), and 3 (2.3%) stillbirths. Pregnancies diagnosed with mixed pattern WD had a lower live birth rate than those diagnosed with WD with isolated hepatic or neurological involvement (P < .001 and P = .004, respectively). While the spontaneous abortion rate decreases with WD treatment, the rate of live birth, stillbirth, premature birth, and low birth weight did not change in the total group. During pregnancy, patients used D-penicillamine, trientine, and/or zinc. Conclusion: With careful monitoring and management by medical professionals, pregnant women diagnosed with WD can still achieve successful pregnancies and improve their quality of life. Cite this article as: Demir K, Örmeci AÇ, Çavuş B, et al. Maternal and fetal outcomes of pregnancies in Wilson’s disease: A single centre real-life experience. Turk J Gastroenterol. Published online October 22, 2025. doi:10.5152/tjg.2025.25448.

  • Open Access

    What are the predictors of malignancy in inflammatory bowel disease?

    by Zülal İsTemi̇hAn, Bi̇lGer Çavuş, Ali̇ Emre Bardak, Ayşe Merve Kirkoğlu, Cansu Kiziltaş, Rüveyda Si̇lAy, İbRahi̇m Volkan Şenkal, Zi̇yA İmAnov, Kenan Nuri̇yEv, Aynure Rüstemzade, et al.

    Background/aimː This study aims to investigate the prevalence of malignancy in patients with inflammatory bowel disease (IBD) followed up in a tertiary reference center. Materials and methodsː IBD patients with at least 6 months of follow-up from the gastroenterology clinic between 2000 and 2022 wereevaluated retrospectively in a tertiary center. Patient information was obtained from the patient registration system. Resultsː There were 697 patients in the study, 320 (45.9%) of these were female. The mean age of the patients at IBD diagnosis was 33.4± 13.1 years. The mean follow-up time was 93.1 ± 64.8 (median 84, IQR (25–75) (36–144)) months. IBD types were as; 315 (45.2%) hadulcerative colitis, and 382 (54.8%) had Crohn’s disease. Before the diagnosis of IBD, 10 patients (1.4%) had a history of malignancy. Theprevalence of malignancy after the diagnosis of IBD was 13 (1.9%). There was a relationship between malignancy and older age, higherBMI, and female sex in survival analysis (p < 0.05). There was no correlation with disease type and malignancy (p = 0.820). When thepatients who developed malignancy in IBD were compared in terms of the immunomodulators and biological agents used by the patients who did not develop malignancy, there was no statistical difference between the two groups (p > 0.05). Conclusionː Older age, higher BMI, and female sex were found to be at risk for the development of malignancy in IBD, although norelationship was found with the use of immunomodulators, biological agents, or disease type.